First patient undergoes Luxturna gene therapy on NHS
Jake Ternet, patient at Moorfields Eye Hospital was the first in the UK to receive the treatment.
Read More
Tag: Luxturna
NICE nod for Novartis’ Luxturna
The treatment has been approved for RPE65-mediated inherited retinal dystrophies.
Read More
EU OKs Novartis’ gene therapy Luxturna for rare retinal disease
Novartis’ Luxturna has been approved by regulators in Europe to treat a rare inherited condition that causes sight loss.
Read More
CHMP puts 13 therapies forward for EU approval
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region, including three orphan medicines.
Read More
Novartis buys access to Spark’s vision loss therapy
Novartis has bought itself rights to Spark Therapeutic’s gene therapy for a certain type of vision loss, in a deal worth up to $170 million.
Read More
FDA OKs first gene therapy for inherited vision loss
Spark Therapeutics’ Luxturna has become the first gene therapy ever to be approved by the US Food and Drug Administration for an inherited condition.
Read More
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
